• BioMarin Pharmaceutical Inc BMRN.OQ reported quarterly adjusted earnings of 95 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of 46 cents. The mean expectation of twenty four analysts for the quarter was for earnings of 71 cents per share. Wall Street expected results to range from 46 cents to $1.00 per share.

• Revenue rose 14.8% to $745.15 million from a year ago; analysts expected $740.72 million.

• BioMarin Pharmaceutical Inc's reported EPS for the quarter was 95 cents​.

• The company reported quarterly net income of $185.69 million.

• BioMarin Pharmaceutical Inc shares had fallen by 9.9% this quarter and lost 3.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 12.3% in the last three months.​

• In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc is $94.50

This summary was machine generated from LSEG data May 2 at 03:41 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)